B-RAF and MEK inhibitor argeted therapy in papillary craniopharyngiomas: results from the French national multicenter study
Alcubierre Dario De, Emmanuel Jouanneau(Hôpital Pierre Wertheimer), Loic Feuvret, C. Mouly(Hôpital Larrey), Gérald Raverot(Université Claude Bernard Lyon 1), Chiara Villa(Centre National de la Recherche Scientifique), François Ducray(Centre National pour la Recherche Scientifique et Technique (CNRST)), Camille Sergeant(Hospices Civils de Lyon), Delphine Larrieu‐Ciron(Institut Claudius Regaud), Grigorios Gkasdaris(Hospices Civils de Lyon), Anthony Joncour(Université de Poitiers), Claire Briet(Centre Hospitalier Universitaire d'Angers), Julien Boetto(Centre National de la Recherche Scientifique), Margaux Mordrel(Université de Poitiers), Bertrand Baussart(Centre National de la Recherche Scientifique), Fabien Almairac(Centre Hospitalier Universitaire de Nice), Alexandre Vasiljevic(Centre de Recherche en Neurosciences de Lyon)
Cited by 0
Related Papers
Intertumoral Heterogeneity within Medulloblastoma Subgroups
|Cancer Cell|2017|1.3k
Clinical Characteristics and Therapeutic Responses in Patients with Germ-Line<i>AIP</i>Mutations and Pituitary Adenomas: An International Collaborative Study
|The Journal of Clinical Endocrinology & Metabolism|2010|374
Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis
|The Lancet Oncology|2016|374
From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal
|Endocrine Related Cancer|2017|357
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
|Journal of Clinical Oncology|2017|345